QDI

UTMB Health Selects Tendo's Data and Analytics Software

Retrieved on: 
Monday, April 8, 2024
UTHealth School of Dentistry, Health, Documentation, CDI, Caregiver, UTMB, Patient, Hospital, University, QDI, Tendō, Nursing

PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Tendo, a software company creating seamless healthcare experiences for patients, clinicians, and caregivers while improving quality, financial, health, and operations outcomes, announces its newest customer, the University of Texas Medical Branch (UTMB Health).

Key Points: 
  • PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Tendo, a software company creating seamless healthcare experiences for patients, clinicians, and caregivers while improving quality, financial, health, and operations outcomes, announces its newest customer, the University of Texas Medical Branch (UTMB Health).
  • Located in Galveston, TX, UTMB Health is a major academic health sciences center of global influence, a world-renowned research enterprise, and a growing, comprehensive health system with hospitals on four campuses and a network of clinics.
  • "UTMB Health already delivers quality clinical care.
  • Tendo's quality suite uses advanced analytics and AI to quickly and accurately identify opportunities for clinical documentation improvement while streamlining clinical workflows and simplifying clinician activities.

MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland

Retrieved on: 
Wednesday, March 27, 2024
Research, Public Policy, Government, Other Natural Resources, Biotechnology, White House, Federal Government, Health, Agriculture, Natural Resources, Science, Other Science, Partnership, HID, RNA, DNA, IVD, QDI, Protein, QIAGEN, Collection, Marketing

MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.

Key Points: 
  • MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.
  • This exclusivity refers to Life Science products for the respective customer base and does not extend to other product portfolios of QIAGEN such as IVD regulated products, HID, Instrument Service or QDI products or customer segments.
  • This new partnership extends QIAGEN’S reach into the Irish life science market by leveraging MyBio Ltd.’s strong commercial presence and deep ties within the Academic, Biopharma and Agri-Bioscience industries in Ireland and Northern Ireland.
  • Under the terms of the agreement, MyBio Ltd. will exclusively supply the QIAGEN Life Science research product range to the academic research, biopharma, and agri-bioscience industries across the Island of Ireland.

QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

Retrieved on: 
Thursday, January 4, 2024
Knowledge, Database, NGS, Protein, Medicine, Natural language, Natural language processing, API, Research, QGEN, Speed of light, QIAGEN, Knowledge base, NLP, Artificial intelligence, AI, QDI, Data science, Gene, CLC, Growth, Investment, Senior

Venlo, the Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business.

Key Points: 
  • Venlo, the Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business.
  • These investments will support QDI, the bioinformatics market leader with sales of approximately $100 million in 2023, to expand its offerings in new geographic regions and market segments while delivering enhanced customer insights and new products.
  • “Our significant investments into QDI demonstrate our commitment to accelerating growth and promoting innovation in the bioinformatics market.
  • Importantly, QDI’s Knowledge Base allows biologists to drive confident analysis and interpretation without requiring bioinformatics expertise.

QIAGEN expands business in Middle East with new regional headquarters and major projects

Retrieved on: 
Wednesday, January 3, 2024
EEMEA, Workforce, TST, TB, CDC, Policy, QCI, Medicine, Commercial, Infection, Cervical cancer, Marketing, QGEN, QIAGEN, WHO, Disease, HPV, Incidence, Latent tuberculosis, Language interpretation, Vaccination, QDI, BCG, Meningitis, Ministry, Public, World Health Organization, Memorandum of understanding, Patient, Bacteria, Gold

“At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.

Key Points: 
  • “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.
  • To accommodate its growing regional presence and customer needs, QIAGEN will inaugurate its new regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024.
  • This office will further strengthen the company’s commitment to the Middle East and improve its ability to serve clients in the area.
  • The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus in all settings to combat the global TB epidemic.

Global NGS Data Storage Market 2023 to 2033: Data Compression Efforts by Companies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Technology, Data Management, Cloud, Informatics, EWG, Amazon Web Services, QIAGEN, Twist Bioscience, Community Cyberinfrastructure for Advanced Microbial Ecology Research and Analysis, Software, Genomics, National Association of Testing Authorities, NGS, COVID-19, NATA, System, Mass meeting, Microsoft, Research, Whole genome sequencing, Sequence, Laboratory, Google Cloud, Algorithm, Twist, QDI, Microsoft Azure, WGS, Growth, Azure, Region, Rare, National Association, WES, Genome, Illumina, Inc., Video game, Pharmaceutical industry

The global NGS data storage market is projected to reach $6.96 billion by 2033 from $1.13 billion in 2022, growing at a CAGR of 18.02% during the forecast period 2023-2033.

Key Points: 
  • The global NGS data storage market is projected to reach $6.96 billion by 2033 from $1.13 billion in 2022, growing at a CAGR of 18.02% during the forecast period 2023-2033.
  • Several companies have developed NGS informatics solutions to aid healthcare institutions and academic research centers.
  • NGS data is critical to researchers that offer storage solutions that are reliable while being easy to manage.
  • These services offer pay-as-you-go models, which make it easier for researchers to manage costs based on their data storage needs.

PIMCO Launches New Preferred and Capital Securities Active Exchange-Traded Fund (PRFD)

Retrieved on: 
Thursday, January 19, 2023
European Credit Research Institute, ETF, PIMCO, Capital, Investment, QDI, NYSE Arca, Research, Security (finance)

The PIMCO Preferred and Capital Securities Active ETF (PRFD) aims to find compelling opportunities in the preferred and capital securities markets where investments may offer equity-like total returns with significantly less volatility – less than half, historically – compared with the traditional stock market.1 In addition, most preferred dividends are considered qualified dividend income (QDI) rather than regular income, which can provide a more favorable tax treatment for investors.

Key Points: 
  • The PIMCO Preferred and Capital Securities Active ETF (PRFD) aims to find compelling opportunities in the preferred and capital securities markets where investments may offer equity-like total returns with significantly less volatility – less than half, historically – compared with the traditional stock market.1 In addition, most preferred dividends are considered qualified dividend income (QDI) rather than regular income, which can provide a more favorable tax treatment for investors.
  • PIMCO’s global trading and research resources, including its team of over 80 research analysts and portfolio management team with 16+ average years of investment experience, search for attractive investment opportunities across the global bank capital, non-financial preferred, and corporate hybrid markets.
  • “Strong balance sheets and higher interest rates make financial institutions, which account for most of the preferred and capital securities market, an attractive investment for those looking for a diversified allocation in fixed income and the potential to earn equity-like returns,” said Mr. Bodereau.
  • PRFD, like many of PIMCO ETF offerings, embraces an active management approach that aims to help investors meet their long-term investment objectives.